Sustained Neuromuscular Blockade after Vecuronium Use in a Premature Infant

 

 Permissions and Reprints

Abstract

Background Prolonged use of neuromuscular blocking agents (NMBAs) is very common in critically ill children both in pediatric and neonatal intensive care units. There are no guidelines available for use of NMBAs in children or neonates in the US, and the data for their safety in this age group is limited.

Case Description Our case describes prolonged neuromuscular blockade following concurrent use of a NMBA along with aminoglycosides and steroids in the setting of renal failure in a premature infant.

Conclusion Prolonged use of NMBAs in preterm infants should be avoided if possible or should be restricted to the shortest possible duration and the smallest possible physiologically effective dose. Concurrent use of NMBAs with aminoglycoside and steroids should be avoided, especially in the setting of renal failure.

• References

• 1 Playfor S, Jenkins I, Boyles C , et al; United Kingdom Paediatric Intensive Care Society Sedation, Analgesia and Neuromuscular Blockade Working Group. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Paediatr Anaesth 2007; 17 (9) 881-887
  CrossrefPubMedGoogle Scholar
• 2 Hodges UM. Vecuronium infusion requirements in paediatric patients in intensive care units: the use of acceleromyography. Br J Anaesth 1996; 76 (1) 23-28
  CrossrefPubMedGoogle Scholar
• 3 Tabarki B, Coffiniéres A, Van Den Bergh P, Huault G, Landrieu P, Sébire G. Critical illness neuromuscular disease: clinical, electrophysiological, and prognostic aspects. Arch Dis Child 2002; 86 (2) 103-107
  CrossrefPubMedGoogle Scholar
• 4 Murray MJ, Brull SJ, Bolton CF. Brief review: Nondepolarizing neuromuscular blocking drugs and critical illness myopathy. Can J Anaesth 2006; 53 (11) 1148-1156
  CrossrefPubMedGoogle Scholar
• 5 Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992; 327 (8) 524-528
  CrossrefPubMedGoogle Scholar
• 6 Warner WA, Sanders E. Neuromuscular blockade associated with gentamicin therapy. JAMA 1971; 215 (7) 1153-1154
  CrossrefPubMedGoogle Scholar
• 7 Johnson PN, Miller J, Gormley AK. Continuous-infusion neuromuscular blocking agents in critically ill neonates and children. Pharmacotherapy 2011; 31 (6) 609-620
  CrossrefPubMedGoogle Scholar
• 8 Dupuis JY, Martin R, Tétrault J-P. Atracurium and vecuronium interaction with gentamicin and tobramycin. Can J Anaesth 1989; 36 (4) 407-411
  CrossrefPubMedGoogle Scholar
• 9 Jedeikin R, Dolgunski E, Kaplan R, Hoffman S. Prolongation of neuromuscular blocking effect of vecuronium by antibiotics. Anaesthesia 1987; 42 (8) 858-860
  CrossrefPubMedGoogle Scholar
• 10 Sokoll MD, Gergis SD. Antibiotics and neuromuscular function. Anesthesiology 1981; 55 (2) 148-159
  CrossrefPubMedGoogle Scholar
• 11 Hibbs RE, Zambon AC. Agents acting at the neuromuscular junction and autonomic ganglia. In: Brunton LL, Chabner BA, Knollmann BC, , eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12e. New York, NY: Mc Graw-Hill; 2011: 255-276 :chap 11
  Google Scholar
• 12 Hirano M, Ott BR, Raps EC , et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992; 42 (11) 2082-2087
  CrossrefPubMedGoogle Scholar
• 13 Dengler R, Rüdel R, Warelas J, Birnberger KL. Corticosteroids and neuromuscular transmission: electrophysiological investigation of the effects of prednisolone on normal and anticholinesterase-treated neuromuscular junction. Pflugers Arch 1979; 380 (2) 145-151
  CrossrefPubMedGoogle Scholar